CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today reported business highlights and financial results for the first quarter of 2017.
“BeiGene has transitioned into a late-stage biotechnology company with the recent initiation of four pivotal clinical trials for our BTK inhibitor BGB-3111 and PD-1 antibody BGB-A317. We also continue to build our capabilities through our agreement with the Guangzhou Development District to establish a commercial-scale biologics manufacturing joint venture and through the expansion of our global team,” said John V. Oyler, Founder, Chief Executive Officer, and Chairman of BeiGene.
